SCHEMBL730567

SCHEMBL730567

Cc1nn(-c2ccccn2)c2sc(C(=O)N3CCC4(CC3)CC(=O)c3cc(-c5nnn[nH]5)ccc3O4)cc12.[NaH]

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TSHR P16473 5/20 0.45
SMN1; SMN2 Q16637 4/20 0.45
ALDH1A1 P00352 4/20 0.45
HPGD P15428 4/20 0.45
CREBBP Q92793 2/20 0.45
MAPT P10636 2/20 0.45
ESR1 P03372 1/20 0.45
HSD17B10 Q99714 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
ACACB O00763 10/20 0.41
HTT P42858 2/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
LMNA P02545 3/20 0.40
USP2 O75604 3/20 0.40
NPSR1 Q6W5P4 3/20 0.40
POLB P06746 1/20 0.40
KDM4E B2RXH2 1/20 0.39
ACACA Q13085 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL733415 0.99 TSHR (0.46) TSHRSMN1; SMN2ALDH1A1HPGDCREBBP
SCHEMBL730568 0.99 TSHR (0.45) TSHRSMN1; SMN2ALDH1A1HPGDCREBBP
SCHEMBL14151406 0.92 ACACB (0.39) TSHRSMN1; SMN2ALDH1A1HPGDCREBBP
SCHEMBL730824 0.91 TSHR (0.42) TSHRSMN1; SMN2ALDH1A1HPGDCREBBP
SCHEMBL731943 0.90 ACACB (0.38) TSHRSMN1; SMN2ALDH1A1HPGDCREBBP
SCHEMBL730690 0.90 ACACB (0.38) TSHRSMN1; SMN2ALDH1A1HPGDCREBBP
SCHEMBL742125 0.86 TSHR (0.48) TSHRSMN1; SMN2ALDH1A1HPGDCREBBP
SCHEMBL309173 0.84 ACACB (0.42) ALDH1A1HPGDHSD17B10ACACBHTT
SCHEMBL730997 0.84 TSHR (0.46) TSHRSMN1; SMN2ALDH1A1HPGDCREBBP
SCHEMBL743886 0.84 ACACB (0.48) TSHRSMN1; SMN2ALDH1A1HPGDCREBBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2120569-B1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME (US) 2013-08-14 EP claimed
US-8138197-B2 Spirochromanon derivatives MSD K.K. (JP) 2012-03-20 US claimed
EP-2120569-A2 SPIROCHROMANON DERIVATIVES Merck & Co., Inc. (US) 2009-11-25 EP claimed
US-20090270436-A1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME LLC 2009-10-29 US claimed
WO-2008088692-A2 SPIROCHROMANON DERIVATIVES MERCK & CO., INC. (US) 2008-07-24 WO claimed
EP-2120569-B1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME (US) 2013-08-14 EP disclosed
US-8138197-B2 Spirochromanon derivatives MSD K.K. (JP) 2012-03-20 US disclosed
EP-2120569-A2 SPIROCHROMANON DERIVATIVES Merck & Co., Inc. (US) 2009-11-25 EP disclosed
US-20090270436-A1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME LLC 2009-10-29 US disclosed
WO-2008088692-A2 SPIROCHROMANON DERIVATIVES MERCK & CO., INC. (US) 2008-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270436-A1 SPIROCHROMANON DERIVATIVES AKR1C3, CBR3, AKR1C4 TSHR 680/4885SMN1; SMN2 3531/4885ALDH1A1 113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.